Patents by Inventor Michael J. P. Lawman
Michael J. P. Lawman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230270860Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.Type: ApplicationFiled: December 1, 2022Publication date: August 31, 2023Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Publication number: 20230183690Abstract: Chimeric expression constructs encoding an immunogenic polypeptide fused to a lactadherin domain are described. The compositions are useful for delivery of antigens to different cells, including cancer cells.Type: ApplicationFiled: November 15, 2022Publication date: June 15, 2023Inventors: EVREN ALICI, MICHAEL J. SHAMBLOTT, MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN
-
Publication number: 20200317764Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.Type: ApplicationFiled: May 8, 2020Publication date: October 8, 2020Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Patent number: 10751400Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: August 26, 2019Date of Patent: August 25, 2020Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Patent number: 10682401Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 1, 2017Date of Patent: June 16, 2020Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous, Michael J. Shamblott
-
Publication number: 20200000901Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: August 26, 2019Publication date: January 2, 2020Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA, MEGHAN GENTILINI
-
Patent number: 10391158Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: December 11, 2017Date of Patent: August 27, 2019Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Publication number: 20180085448Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: December 11, 2017Publication date: March 29, 2018Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Patent number: 9839680Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: January 30, 2017Date of Patent: December 12, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya
-
Publication number: 20170232090Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: ApplicationFiled: May 1, 2017Publication date: August 17, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Publication number: 20170136109Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: January 30, 2017Publication date: May 18, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA
-
Patent number: 9636388Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 19, 2016Date of Patent: May 2, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous
-
Publication number: 20170042993Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: ApplicationFiled: May 19, 2016Publication date: February 16, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS
-
Patent number: 9555088Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: March 4, 2015Date of Patent: January 31, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya
-
Publication number: 20160361400Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: March 4, 2015Publication date: December 15, 2016Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA
-
Publication number: 20140377172Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.Type: ApplicationFiled: March 4, 2010Publication date: December 25, 2014Applicant: Morphogenesis, Inc.Inventors: Michael J.P. Lawman, Patricia Lawman
-
Publication number: 20120289456Abstract: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of activity against MDR strains tested, including methicillin resistant Staphylococcus aureus (MRSA).Type: ApplicationFiled: February 10, 2012Publication date: November 15, 2012Applicant: ST. JOSEPH'S CHILDREN'S HOSPITALInventors: MICHAEL J. P. LAWMAN, Selena Savell, Shabnam Eidizadeh
-
Patent number: 8030069Abstract: The subject invention provides new materials and methods for the efficient isolation and purification of stem cells. Specifically, conductive immunopolymers with stem cell specific antibodies can be used to remove stem cells from biological fluids.Type: GrantFiled: April 24, 2009Date of Patent: October 4, 2011Assignee: Morphogenesis, Inc.Inventors: Michael J. P. Lawman, Patricia D. Lawman
-
Patent number: 7795020Abstract: An effective cancer cell vaccine for canines has been developed. The vaccine is prepared from autologous lymphoma cells transfected with emm55. Once an animal is vaccinated, the expressed Emm55 antigen stimulates an immunogenic response to the tumor cells resulting in significantly increased survival, strong autologous and cross reactive humoral and cell mediated responses in several breeds of dogs diagnosed with later stage lymphomas.Type: GrantFiled: March 17, 2008Date of Patent: September 14, 2010Assignee: Morphogenesis, Inc.Inventors: Michael J. P. Lawman, Patricia Lawman
-
Patent number: 7709000Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.Type: GrantFiled: July 16, 2007Date of Patent: May 4, 2010Assignee: Morphogenesis, Inc.Inventors: Michael J. P. Lawman, Patricia Lawman